Jennifer Lachey - 04 Nov 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
04 Nov 2021
Net transactions value
-$526,820
Form type
4
Filing time
05 Nov 2021, 17:06:39 UTC
Previous filing
18 Aug 2021
Next filing
12 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $3,180 +10,600 +12% $0.3000* 96,300 04 Nov 2021 Direct
transaction KROS Common Stock Sale $530,000 -10,600 -11% $50.00 85,700 04 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -10,600 -8.2% $0.000000 119,105 04 Nov 2021 Common Stock 10,600 $0.3000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.